O
PTGX icon

OrbiMed’s Protagonist Therapeutics PTGX Stock Holding History

OrbiMed’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Hold
42,100
– – 0.1% 102
2026
Q1 		$4.44M Buy
42,100
+20,400
+94% +$1.81M 0.09% 96
2025
Q4 		$1.9M Buy
+21,700
New +$1.78M 0.04% 102
2023
Q2 		– Sell
-301,000
Closed -$6.92M – 133
2023
Q1 		$6.92M Buy
+301,000
New +$5.06M 0.14% 93
2020
Q2 		– Sell
-66,909
Closed -$472K – 150
2020
Q1 		$472K Sell
66,909
-124,300
-65% -$931K 0.01% 139
2019
Q4 		$1.35M Buy
+191,209
New +$1.9M 0.02% 125

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

OrbiMed's PTGX Position: Q2 2026 in Review

OrbiMed held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 42,100 shares worth $5.16M. The position accounts for 0.1% of the portfolio, ranked #102.

OrbiMed first reported a position in PTGX in Q4 2019 and has held it in 6 quarters since. The position peaked at $6.92M in Q1 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • OrbiMed held 42,100 shares of Protagonist Therapeutics worth $5.16M as of Q2 2026.
  • OrbiMed left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up 0.1% of OrbiMed's portfolio in Q2 2026, its #102 holding.
  • OrbiMed first reported a position in Protagonist Therapeutics in Q4 2019 and has held it in 6 quarters since.
  • OrbiMed's Protagonist Therapeutics position peaked at $6.92M in Q1 2023.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.